News stories about Globus Medical (NYSE:GMED) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Globus Medical earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned headlines about the medical device company an impact score of 45.4165484302346 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Globus Medical, Inc. :GMED-US: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017 (finance.yahoo.com)
- See what the IHS Markit Score report has to say about Globus Medical Inc. (finance.yahoo.com)
- Reviewing Globus Medical (GMED) & Integer Holdings (ITGR) (americanbankingnews.com)
- Financial Comparison: Globus Medical (GMED) and AxoGen (AXGN) (americanbankingnews.com)
- Zacks: Analysts Anticipate Globus Medical, Inc. (GMED) to Announce $0.30 Earnings Per Share (americanbankingnews.com)
Several equities research analysts recently commented on GMED shares. Zacks Investment Research lowered shares of Globus Medical from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Globus Medical in a research note on Thursday, May 18th. Canaccord Genuity raised shares of Globus Medical from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $30.00 to $37.00 in a research note on Thursday, May 4th. Barclays PLC lowered shares of Globus Medical from an “equal weight” rating to an “underweight” rating and boosted their price objective for the stock from $24.00 to $28.00 in a research note on Monday, April 24th. Finally, BidaskClub lowered shares of Globus Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Three analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company’s stock. Globus Medical currently has a consensus rating of “Hold” and an average target price of $30.43.
Shares of Globus Medical (GMED) traded up 1.81% on Friday, reaching $29.30. 610,322 shares of the company’s stock traded hands. Globus Medical has a 12-month low of $19.25 and a 12-month high of $34.03. The stock has a 50-day moving average price of $31.79 and a 200-day moving average price of $30.14. The company has a market cap of $2.82 billion, a PE ratio of 26.40 and a beta of 0.60.
Globus Medical (NYSE:GMED) last released its quarterly earnings results on Wednesday, August 2nd. The medical device company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.30 by $0.02. Globus Medical had a net margin of 18.12% and a return on equity of 13.99%. The business had revenue of $152.39 million for the quarter, compared to analysts’ expectations of $150.94 million. During the same period last year, the business earned $0.29 EPS. The company’s revenue was up 10.8% compared to the same quarter last year. Equities research analysts anticipate that Globus Medical will post $1.27 EPS for the current fiscal year.
In other news, President Anthony L. Williams sold 16,153 shares of the firm’s stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $31.94, for a total value of $515,926.82. Following the sale, the president now directly owns 16,153 shares in the company, valued at approximately $515,926.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 28.21% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Stock Observer and is owned by of Stock Observer. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.thestockobserver.com/2017/08/12/globus-medical-gmed-receives-media-impact-rating-of-0-18.html.
About Globus Medical
Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.
Receive News & Ratings for Globus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.